Author: Cho, Sung-Yeon; Lee, Hyeon-Jeong; Lee, Dong-Gun
Title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea Document date: 2018_2_27
ID: t9tysvr8_2
Snippet: Until the 1970s, HSCTs were simply classified as au- tologous or allogeneic according to their donor status, and survival rates were very low. Since the introduction of the human leukocyte antigen (HLA) concept, the incidence of graft failure and/or graft-versus-host disease (GVHD) has decreased. In recent years, allogeneic HSCT has involved various sources of hematopoietic stem cells (bone marrow, peripheral stem cell, cord blood, and mesenchyma.....
Document: Until the 1970s, HSCTs were simply classified as au- tologous or allogeneic according to their donor status, and survival rates were very low. Since the introduction of the human leukocyte antigen (HLA) concept, the incidence of graft failure and/or graft-versus-host disease (GVHD) has decreased. In recent years, allogeneic HSCT has involved various sources of hematopoietic stem cells (bone marrow, peripheral stem cell, cord blood, and mesenchymal cells), donors (sibling, unrelated, haploidentical), and conditioning regimens (standard [myeloablative], reduced intensity). Supportive therapies such as transfusion, colony stimulating factors, and antimicrobial agents have also been developed. Although various early diagnosis and therapeutic techniques have been developed to improve transplant performance, infectious diseases still affect the prognosis of HSCT recipients [2] [3] [4] .
Search related documents:
Co phrase search for related documents- infectious disease and recent year: 1, 2, 3, 4
- infectious disease and reduced intensity: 1
- infectious disease and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- infectious disease and supportive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- infectious disease and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- mesenchymal cell and peripheral stem cell: 1
- mesenchymal cell and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- mesenchymal cell and supportive therapy: 1, 2, 3
- mesenchymal cell and survival rate: 1, 2, 3
- mesenchymal cell cord blood and stem cell: 1, 2
- peripheral stem cell and reduced intensity: 1, 2, 3
- peripheral stem cell and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- recent year and supportive therapy: 1
- recent year and survival rate: 1, 2, 3, 4
- reduced intensity and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- reduced intensity and survival rate: 1, 2
- stem cell and supportive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- stem cell and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- supportive therapy and survival rate: 1
Co phrase search for related documents, hyperlinks ordered by date